Singapore markets closed

Telomir Pharmaceuticals, Inc. (TELO)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
6.05+0.05 (+0.83%)
At close: 04:00PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
Total revenue
0
0
0
0
Operating expenses
Research development
1,938
1,574
833.206
126.492
Selling general and administrative
1,299
600.192
20.941
11.639
Total operating expenses
5,375
3,942
854.147
138.131
Operating income or loss
-5,375
-3,942
-854.147
-138.131
Interest expense
5,982
1,643
0
-
Total other income/expenses net
-
-7,487
-
-
Income before tax
-18,844
-13,072
-854.147
-138.131
Income from continuing operations
-18,844
-13,072
-854.147
-138.131
Net income
-18,844
-13,072
-854.147
-138.131
Net income available to common shareholders
-18,844
-13,072
-854.147
-138.131
Basic EPS
-0.14
-0.44
-0.03
-0.00
Diluted EPS
-0.14
-0.44
-0.03
-0.00
Basic average shares
29,610
29,610
29,610
29,610
Diluted average shares
29,610
29,610
29,610
29,610